Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Hepatitis B and C Seroprevalence in Solid Tumors - Necessity for Screening During Chemotherapy

  • Oguz, Arzu (Baskent University, Medical Oncology Department) ;
  • Aykas, Fatma (Kayseri Education and Research Hospital, Internal Medicine Clinic) ;
  • Unal, Dilek (Kayseri Education and Research Hospital, Radiation Oncology Clinic) ;
  • Karahan, Samet (Kayseri Education and Research Hospital, Internal Medicine Clinic) ;
  • Uslu, Emine (Kayseri Education and Research Hospital, Internal Medicine Clinic) ;
  • Basak, Mustafa (Kayseri Education and Research Hospital, Internal Medicine Clinic) ;
  • Karaman, Ahmet (Kayseri Education and Research Hospital, Gastroenterology Clinic)
  • Published : 2014.02.01
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Hepatitis B and C are the leading causes of liver diseases worldwide. For hematological and solid malignancy patients undergoing chemotherapy, increases in HBV DNA and HCV RNA levels can be detected which may result in reactivation and hepatitis-related morbidity and mortality. The aim of this study was to determine the seroprevalence of Hbs ag and Anti HCV positivity in patients with solid malignancies undergoing chemotherapy and consequences during follow-up. Materials and Methods: The files of 914 patients with solid malignancies whose hepatitis markers were determined serologically at diagnosis were reviewed retrospectively. All underwent adjuvant/palliative chemotherapy. For the cases with HBV and/or HCV positivity, HBV DNA and HCV RNA levels, liver function tests at diagnosis and during follow-up and the treatment modalities that were chosen were determined. Results: Of 914 cases, Hbs Ag, anti Hbs and anti HCV positivity were detected in 40 (4.4%), 336 (36.8%) and 26 (2.8%) of the cases respectively. All of the Hbs ag positive patients received prophylactic lamuvidine before the start of chemotherapy. In the Hbs ag and anti HCV positive cases, liver failure was not detected during chemotherapy and a delay in chemotherapy courses because of hepatitis was not encountered. Conclusions: Just as with hematological malignancies, screening for HBV and HCV should also be considered for patients with solid tumors undergoing chemotherapy. Prophylactic antiviral therapy for HBV reduces both the reactivation rates and HBV related mortality and morbidity. The clinical impact of HCV infection on patients undergoing chemotherapy is still not well characterized.

Keywords

References

  1. Alagozlu H, Ozdemir O, Koksal B, Yilmaz A, Coskun M (2013). Prevelance of common YMDD motif mutations in long term treated chronic HBV infections in a Turkish population. Asian Pac J Cancer Prev, 14, 5489-94. https://doi.org/10.7314/APJCP.2013.14.9.5489
  2. Alexopoulos CG, Vaslamatzis M, Hatzidimitriou G (1999). Prevalence of hepatitis B virus marker positivity and evolution of hepatitis B virus profile, during chemotherapy, in patients with solid tumors. Br J Cancer, 81, 69-74. https://doi.org/10.1038/sj.bjc.6690652
  3. Arcaini L, Merli M, Passamonti F, et al (2010). Impact of treatment related liver toxicity on the outcome of HCV-positive non-Hodgkin's lymphomas. Am J Hematol, 85, 46-50.
  4. Besson C, Canioni D, Lepage E, et al (2006). Characteristics and outcome of diffuse large B-cell lymphoma in hepatitis C virus-positive patients in LNH 93 and LNH 98 Groupe d'Etude des Lymphomes de l'Adulte programs. J Clin Oncol, 24, 953-60. https://doi.org/10.1200/JCO.2005.01.5016
  5. Cainelli F, Longhi MS, Concia E, Vento S (2001). Failure of lamuvidine therapy for chemotherapy induced reactivation of hepatitis. Am J Gastroenterol, 96, 1651-2. https://doi.org/10.1111/j.1572-0241.2001.03824.x
  6. Clark FL, Drummond MW, Chambers S, Chapman BA, Patton WN (1998). Successful treatment with lamuvidine for fulminant reactivated hepatitis B infection following intensive therapy for high-grade non-Hodgkin's lymphoma. Ann Oncol, 9, 385-7. https://doi.org/10.1023/A:1008206519571
  7. Custer B, Sullivan SD, Hazlet TK, et al (2004). Global epidemiology of hepatitis B virus. J Clin Gastroenterol, 38, 158-68. https://doi.org/10.1097/00004836-200411003-00008
  8. European Association for the Study of the Liver (2011). EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol, 55, 245-64. https://doi.org/10.1016/j.jhep.2011.02.023
  9. Gurol E, Saban C, Oral O, Cigdem A, Armagan A (2006). Trends in hepatitis B and hepatitis C virus among blood donors over 16 years in Turkey. Eur J Epidemiol, 21, 299-305. https://doi.org/10.1007/s10654-006-0001-2
  10. Hwang YY, Liang RH (2010). Hepatitis C in haematological patients. Hepat Res Treat, 2010, 961359.
  11. Kanamori H, Fukawa H, Maruta A, et al (1992). Case report: fulminant hepatitis C viral infection after allogeneic bone marrow transplantation. Am J Med Sci, 303, 109-11. https://doi.org/10.1097/00000441-199202000-00009
  12. Kohrt HE, Ouyang DL, Keeffe EB (2006). Systematic review: lamuvidine prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection. Aliment Pharmacol Ther, 24, 1003-16. https://doi.org/10.1111/j.1365-2036.2006.03081.x
  13. Kose S, Olmezoglu A, Gozaydin A, Ece G (2011). Seroprevalence of Hepatitis B and C among oncology patients in Turkey. J Health Popul Nutr, 29, 652-5.
  14. Kumagai K, Takagi T, Nakamura S, et al (1997). Hepatitis B virus carriers in the treatment of malignant lymphoma: an epidemiological study in Japan. Ann Oncol, 8, 107-9. https://doi.org/10.1023/A:1008234807768
  15. Lau GK, Yiu HH, Fong DY, et al (2003). Early is superior to deferred preemptive lamuvidine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterol, 125, 1742-9. https://doi.org/10.1053/j.gastro.2003.09.026
  16. Lavanchy D (2004). Hepatitis B virus epidemiology, disaese burden, treatment and current and emerging prevention and control measures. J Viral Hepat, 11, 97-107. https://doi.org/10.1046/j.1365-2893.2003.00487.x
  17. Long M, Jia W, Li S, et al (2011). A single center, prospective and randomized controlled study: Can the prophylactic use of lamuvidine prevent hepatitis B virus reactivation in hepatitis B s-antigen seropositive breast cancer patients during chemotherapy? Breast Cancer Res Treat, 127, 705-12. https://doi.org/10.1007/s10549-011-1455-9
  18. Loomba R, Rowley A, Wesley R, et al (2008). Systematic review: the effect of preventive lamuvidine on Hepatitis B reactivation during chemotherapy. Ann Intern Med, 148, 519-28. https://doi.org/10.7326/0003-4819-148-7-200804010-00008
  19. Mehmet D, Meliksah E, Serif Y, et al (2005). Prevalence of hepatitis B infection in the southeast region of Turkey: comparison of risk factors in rural and urban areas. Jpn J Infect Dis, 58, 15-9.
  20. Nakamura Y, Motokura T, Fujita A, Yamashita T, Ogata E (1996). Severe hepatitis related to chemotherapy in hepatitis B virus carriers with hematologic malignancies. Survey in Japan, 1987-1991. Cancer, 78, 2210-5. https://doi.org/10.1002/(SICI)1097-0142(19961115)78:10<2210::AID-CNCR24>3.0.CO;2-0
  21. Persico M, De Marino F, Russo GD, et al (2002). Efficacy of lamuvidine to prevent hepatitis reactivation in hepatitis B virus-infected patients treated for non-Hodgkin lymphoma. Blood, 99, 724-5. https://doi.org/10.1182/blood.V99.2.724
  22. Soh LT, Ang PT, Sng I, Chua EJ, Ong YW (1992). Fulminant hepatic failure in non-Hodgkin lymphoma patients treated with chemotherapy. Eur J Cancer, 28, 1338-9. https://doi.org/10.1016/0959-8049(92)90513-2
  23. Steinberg JL, Yeo W, Zhong S, et al (2000). Hepatitis B virus reactivation in patients undergoing cytotoxic chemotherapy for solid tumors: procore/core mutations may play an important role. J Med Virol, 60, 249-55. https://doi.org/10.1002/(SICI)1096-9071(200003)60:3<249::AID-JMV1>3.0.CO;2-C
  24. Ter Borg F, Smorenburg S, de Man RA, et al (1998). Recovery from life threatening, corticosteroid-unresponsive, chemotherapy-related reactivation of hepatitis B associated with lamuvidine therapy. Dig Dis Sci, 43, 2267-70. https://doi.org/10.1023/A:1026622807373
  25. Utkan G, Azap A, Muallaoglu S, et al (2006). Hepatitis B and C in cancer patients: case-control study. Int J Hematol Oncol, 16, 103-7.
  26. Uzun K, Alici S, Ozbay B, Gencer M, Irmak H (2002). The incidence of hepatitis C virus in patients with lung cancer. Turkish Respiratory J, 3, 91-3.
  27. Vento S, Cainelli F, Mirandola F, et al (1996). Fulminant hepatitis on withdrawal of chemotherapy in carriers of hepatitis C virus. Lancet, 347, 92-3. https://doi.org/10.1016/S0140-6736(96)90212-3
  28. Yazici Y, Demir N, Cinarka H, Yilmaz H, Altintas N (2010). Seroprevalences of HBV, HCV and HIV among healthcare workers of Trabzon Chest Diseases Hospital. Turkish Bull Hyg Experiment Biol, 67, 27-32.
  29. Yeo W, Chan PK, Zhong S, et al (2000). Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol, 62, 299-307. https://doi.org/10.1002/1096-9071(200011)62:3<299::AID-JMV1>3.0.CO;2-0
  30. Yeo W, Chan PK, Hui P, et al (2003). Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: a prospective study. J Med Virol, 70, 553-61. https://doi.org/10.1002/jmv.10430
  31. Yeo W, Ho WM, Hui P, et al (2004). Use of lamuvidine to prevent hepatitis B virus reactivation during chemotherapy in breast cancer patients. Breast Cancer Res Treat, 88, 209-15. https://doi.org/10.1007/s10549-004-0725-1
  32. Yeo W, Johnson PJ (2006). Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology, 43, 209-20. https://doi.org/10.1002/hep.21051
  33. Zuckerman E, Zuckerman T, Douer D, Qian D, Levine AM (1998). Liver dysfunction in patients infected with hepatitis C virus undergoing chemotherapy for hematologic malignancies. Cancer, 83, 1224-30. https://doi.org/10.1002/(SICI)1097-0142(19980915)83:6<1224::AID-CNCR23>3.0.CO;2-6

Cited by

  1. Prevalence of hepatitis B and C and sensibility of a selective screening questionnaire in patients receiving chemotherapy for solid tumors vol.15, pp.1, 2015, https://doi.org/10.1186/s12885-015-2033-z
  2. The oncologic burden of hepatitis C virus infection: A clinical perspective vol.67, pp.5, 2017, https://doi.org/10.3322/caac.21403